Using three microfluidic devices coated with antibodies against markers expressed in AML (CD33, CD34, and CD117) and aberrant markers (CD7 and CD56) at 39 MRD points, they achieved satisfactory results with the detection of relapse signs being faster than tests based on bone marrow samples. Here, NCAM1 is linked to acute myeloid leukemia.